PRISM Mentors

The Wang Lab takes an interdisciplinary approach to studying fundamental mechanisms controlling gene expression in mammalian cells. Our work shows how epigenetic mechanisms such as DNA methylation, chromatin modifications, and RNA influence chromatin dynamics to affect gene regulation. OUR LAB IS CURRENTLY FOCUSED ON: How various dynamic epigenetic changes in chromatin structure impact gene expression during stem cell pluripotency/self-renewal, cellular differentiation, and reprogramming; How three-dimensional chromosomal structure and dysregulation contribute to development of diseases such as aging and cancer; and How to create novel genome engineering tools to interrogate the noncoding genome and the epigenome.
 
The long-term goal of The Wang Lab is to translate our understanding of these complex mechanisms to studies of human diseases.

Our laboratory studies the mechanisms by which highly complex behaviors are mediated at the neuronal level, mainly focusing on the example of dynamic social interactions and the neural circuits that drive them. From dyadic interactions to group dynamics and collective decision making, the lab seeks a mechanistic understanding for the fundamental building blocks of societies, such as cooperation, empathy, fairness and reciprocity. The computations underlying social interactions are highly distributed across many brain areas. Our lab is interested in which specific areas are involved in a particular function, why such an architecture arises and how activity in multiple networks is coordinated. Our goal is to develop a roadmap of the social brain and use it for guiding restorative treatments for conditions in which social behavior is impaired, such as Autism Spectrum Disorders and Schizophrenia.

Professor Gaffney leads a research team focused on femtosecond resolution measurements of chemical dynamics in complex condensed phase systems. This research takes advantage of recent advances in ultrafast x-ray lasers, like the LCLS at SLAC National Accelerator Laboratory, to directly observe chemical reactions on the natural time and length scales of the chemical bond – femtoseconds and Ångströms. This research focuses on the discovery of design principles for controlling the non-equilibrium dynamics of electronic excited states and using these principles to spark new approaches to light-driven catalysis in chemical synthesis.

This research builds on Professor Gaffney’s extensive experience with ultrafast optical laser science and technology. This work began with time- and angle- resolved two photon photoemission studies of electron solvation and localization at interfaces as a graduate student working with Professor Charles Harris at the University of California at Berkeley and extended to multidimensional vibrational spectroscopy studies of hydrogen bonding and ion solvation dynamics in solution during postdoctoral studies with Professor Michael Fayer at Stanford and as an Assistant Professor. The transition to ultrafast x-ray science began in 2004 at SLAC, where he helped establish the first chemical dynamics research program at SLAC.

The Svensson Laboratory is dedicated to the discovery of new fundamental pathways that regulates cellular and organismal metabolism. The main focus is to identify novel functions for new molecules controlling the regulation of glucose and lipid homeostasis using a combination of genomic, proteomic and physiology approaches.

The Sakamoto lab studies normal and aberrant blood cell development. Her research team is interested in the pathogenesis of acute and chronic leukemia, including acute myeloid leukemia and chronic myeloid leukemia. The overall goal of her research is to understand the signaling pathways that lead to leukemia or bone marrow failure. She is also interested in developing new drugs to treat these diseases. Her group experience works with mammalian cells and mouse models of cancer and bone marrow failure syndromes, such as Diamond Blackfan Anemia. There are opportunities to work with physicians, translational researchers, medicinal chemists, and advisors from drug companies with experience in drug development.

Experiments utilize leukemia cell lines, primary mouse and human hematopoietic cells, and mouse models will be used.   Technologies in the lab include standard biochemical techniques (Western blot analysis, real-time PCR, immunoprecipitations), FACs/sorting, colony assays, lentiviral and retroviral transductions, transplantation experiments, xenograft models and bioluminescence, CyTOF, RNA-seq ,ChIP-seq, small molecule and  shRNA/CRISPR library screening. Knowledge in bioinformatics would be helpful for single cell RNA-seq experiments. The intent of these early translational studies is to develop small molecules or peptides into drugs to treat acute leukemia.  Assays to assess toxicity, metabolism, optimization, and mechanism of action of compounds are performed.

Dr. Sakamoto is committed to diversity and has trained many underrepresented high school, undergraduate, medical, graduate students and postdoctoral/MD fellows. She has served on the American Society of Hematology Minority Medical Student Program and was Chair of the Diversity Special Interest Group. She is currently working with SMASH Rising to recruit underrepresented high school graduates and community college students to Stanford to study clinical, translational, and basic hematology. 

The Poston Lab seeks to understand the biological underpinnings of non-motor symptoms in patients with Lewy Body diseases, such as Parkinson's disease and Lewy Body Dementia. While our primary focus is understanding cognition and dementia, we also study other prominent non-motor symptoms such as psychosis/hallucinations, sleep disruption, orthostatic dysregulation, and others.  A major focus is on the role of co-pathologies, such as Alzheimer's and vascular co-pathologies, and the role of neuro-inflammation, in the development of Lewy Body disease associated non-motor symptoms.  We collect clinical, motor, neuropsychological, biological, genetic, and imaging data on patients and healthy older adults to perform our studies. 

Katherine Whittaker Ferrara is a Professor of Radiology and the Division Chief for the Molecular Imaging Program at Stanford. She is a member of the National Academy of Engineering and a fellow of the IEEE, American Association for the Advancement of Science, the Biomedical Engineering Society, the World Molecular Imaging Society, the Acoustical Society of America and the American Institute of Medical and Biological Engineering. Dr. Ferrara received her Ph.D. in 1989 from the University of California, Davis. Prior to her PhD, Dr. Ferrara was a project engineer for General Electric Medical Systems, involved in the development of early magnetic resonance imaging and ultrasound systems. Following an appointment as an Associate Professor in the Department of Biomedical Engineering at the University of Virginia, Charlottesville, Dr. Ferrara served as the founding chair of the Department of Biomedical Engineering at UC Davis. Her laboratory is known for work in molecular imaging and drug delivery.

The Davis laboratory is looking for post-doctoral scholars interested in the study of cancer. We use single-cell, high-dimensional approaches in primary patient materials to identify cells associated with poor clinical outcomes. We have a focus on childhood leukemia, neuroblastoma and Ewing sarcoma. Once identified, we can further interrogate mechanisms of resistance in candidate cell populations and develop new approaches for treatment. 

We are looking for motivated and talented computational biologists and cancer biologists with interest in joining our active group. In particular, opportunties for data scientists/computational biologists are available. 

My research utilizes multimodal imaging (fMRI, dMRI, qMRI), computational modeling, and behavioral measurements to investigate human visual cortex. We seek to understand how the underlying neural mechanisms and their anatomical implementation enable rapid and efficient visual perception and recognition. Critically, we examine how the human brain and visual perception change across development to understand how the interplay between anatomical constraints and experience shapes visual cortex and ultimately behavior.

We strive to create a lab that reflects the diversity of our global community and is actively involved in solving scientific and societal problems that affect all of us. I am also involved in the Wu Tsai Neurosciences Institute and the Ophthalmology T32 training grant.

How are nutrients recognized by their protein sensors? How is their transport across cellular and intracellular membranes regulated? And, how is nutrient sensing integrated with other chemical signals, such as hormones, to determine cellular decisions, especially the decision: to grow or not to grow?

We are a team of structural and chemical biologists aiming to answer these fundamental questions at the level of ångstroms, nanometers, and micrometers. Many proteins in these pathways are deregulated in cancer, and our mission is to first reveal the mechanism of action of these proteins, and then use that knowledge to develop targeted chemical probes to modulate their activity in cells and organisms.

Our lab is friendly to trainees from all walks of life, and we cherish trust, inclusiveness and intellectual curiosity, where no question is too big to study, as long as we have the right approach and a unique angle. Most importantly, our lab operates with a growth mindset for all of our trainees, and we put a heavy emphasis on training and skills development — across a wide range of experimental and computational techniques. And through collaboration, strong work ethic, seeking feedback, and trying out new strategies, we drive innovation and novel discoveries for our team.

If this is something you might be interested in, please contact Kacper directly. We are always on the lookout for driven postdocs! Especially, we want cell biologists and biochemists to join our team and to contribute your unique skillsets to a number of collaborative projects.

I study how ecological communities assemble and influence ecosystem processes, focusing on the role of microbial symbioses, which are ubiquitous in plants and animals. My research is driven primarily by intellectual curiosity about the unseen organisms that shape our planet, but is also aimed to provide knowledge that can be used to better manage ecosystem responses to global change, agriculture, and human health.
My lab uses a combination of ecological theory, molecular biology techniques, and field and laboratory experiments to study microbial communities. Our lab works across a large range of systems, both geographically and ecologically. We work on a number of local projects in the SF Bay Area, across North America, and in tropical rainforests of South American and Southeast Asia. We also study a wide range of interactions, from decomposer bacteria and fungi that are key agents of elemental cycling, to pathogenic fungi  and mutualistic fungi. While I am open to working on a variety of systems, a large portion of my work has  focused on root-fungal mutualisms, known  as mycorrhizal symbiosis, because nearly all plants species, including >98% of all trees, use these partnerships to acquire the soil macronutrients that most limit plant growth and ecosystem productivity. While we now know that such microbial mutualisms are common, there has been far less ecological research on mutualisms compared with antagonistic interactions, such as competition and predation. I ask (a) what controls mycorrhizal community assembly across spatial scales, (b) how mycorrhizal symbiosis structures plant communities, and (c) how mycorrhizal symbiosis is linked to ecosystem processes. By integrating these three topics I seek to build a roots-to-biomes understanding of ecological communities and ecosystem function.

Diabetes is a disorder of glucose homeostasis that causes excess hospitalization, morbidity and early mortality among the more than 34.2 million disease-affected Americans. Consequently, developing pharmacologic methods to preserve β-cell function and/or stimulate β-cell mass expansion is of intense interest. Presently, the creation of improved diabetes medications is stymied by a dearth of safe therapeutic targets. In fact, on-target but off-tissue drug effects are slowing progress across multiple diabetes therapeutic domains including β-cell regeneration, β-cell preservation, and immune-protection. In principle, stimulating the regeneration of insulin-producing β-cells could be used to restore or enhance endogenous insulin production capacity. Recently, we developed several new highly potent chemical inducers of human β-cell proliferation. However, the non-selective growth-promoting activity of these molecules prevents further clinical development. Consequently, a “modular” (readily transferable) system for β-cell-targeted drug delivery is needed to realize the next generation of diabetes therapeutics. To address this challenge, we are developing a β-cell-targeted drug delivery module based upon the uniquely high zinc content of β-cells. In this system, a zinc-chelating moiety is covalently integrated into a replication-promoting (cargo) compound to generate a bi-functional compound (βRepZnC) that selectively enhances β-cell drug accumulation and replication-promoting activity (PMID: 30527998).

We are seeking a motivated post-doctoral scholar to join our collaborative research team. This scientist will lead and engage  in developing novel βRepZnCs and uncover the biology of β-cell failure. They will define the chemical “rules” that govern zinc-dependent β-cell drug targeting,  examine the in vivo β-cell selectivity (accumulation and replication-promoting activity) of  newly developed βRepZnCs (work is supported by a synthtic chemist) and use CRISPR technology to genetically dissect the pathways that control β-cell zinc and zinc-binding drug accumulation. These studies will a break-through technology for β-cell-targeted drug delivery and provide fundamental (targetable) insights into β-cell biology. This work has the potential to transform our therapeutic approach to diabetes and provide critical insights into β-cell biology.

Epilepsy affects ~1% of all children and is defined by recurrent, unprovoked seizures, impaired cognitive abilities, and diminished quality of life. The predisposition for seizures is thought to result from abnormal plasticity and excessive synchrony in affected neural networks. Myelin plasticity is a newly recognized mode of activity-dependent neural network adaptation. The potential for dysregulated myelin plasticity in disease states such as epilepsy is unexplored. Myelination of axons increases conduction velocity and promotes coordinated network function including oscillatory synchrony. During and after age-dependent developmental myelination, increases in myelin occur when humans and rodents acquire new skills. While adaptive myelin plasticity modulates networks to support function in the healthy state, it is unknown whether this process also contributes to network dysfunction in neurological disease.

The Knowles lab conducts basic, translational and clinical research to study how seizures shape white matter, and how changes in white matter shape the course of epilepsy and its comorbidities. We discovered that generalized (absence) seizures induce aberrant myelination that promotes seizure progression. Thus, maladaptive myelination may be a novel pathogenic mechanism in epilepsy and other neurological diseases.  Using innovative imaging, electrophysiological, histological and molecular biology techniques, we are studying multiple questions.

How does white matter structure change throughout the brain over the course of epilepsy?
How does white matter structure impact network synchronization, seizures and cognition?
What signaling pathways underlie aberrant white matter plasticity in different forms of epilepsy?
What can we learn from white matter changes found with various imaging modalities in humans with epilepsy?

We are generally interested in the mechanisms that drive the proliferation of cells under physiological and pathological conditions. We work on a wide range on projects from fundamental cell cycle mechanisms related to the RB pathway to pre-clinical cancer studies. We leverage publicly-available cancer genomics data and generate our own set of genetic, epigenetic, and proteomic data sets to identify novel regulators of cancer growth. We also develop novel genetic approaches in mice to conclusively determine the function of these candidate genes and pathways in tumorigenesis in vivo. Finally, we team up with pharmaceutical companies and clinicians in academic centers to translate our discoveries into the clinic as rapidly as possible.

I am an infectious diseases physician and epidemiologist    OUr lab is well know internationally in two major areas:  1.  The role of infections in chronic diseases and 2.  Physiologic changes in humans over time, specifically the decrease in human body temperature.  3. Novel surveillance projects, especially serosurveys done through the mail and  the use of wastewater to track infections.  Right now, projects that could integrate a post-doctoral fellow include:  In addition, my research group works on gun violence prevention.  

1.  Analysis of a California population-based serosurvey on SARS-COV2 infection, including information on human behaviors (mask wearing, social , vaccination) and demographics (age, race, education),  We could expand this study to look at other infectious diseases as well.

2.  Research assessing the association between high normal body temperature and longevity.

3.  Gun violence prevention.  Gun violence is a national tragedy.  We have two major projects in this area:

     a.  A project with Santa Clara County Department of Public health that combines the many data sources on gun violence across the county (Police, hospitals,EMT, schools, health departments), bring together stakeholders at community organizations across the county fighting gun violence and work with health care workers to identify strategies to educate patients on gun violence prevention.

     b.  Educational project development to teach physicians across the county how to talk to patients about gun violence

Dr. Parsonnet is an Infectious Diseases epidemiologist and clinician.  The Parsonnet lab works to understand how infectious agents influence the development of chronic diseases.  During the COVID crisis, the lab has also been actively involved in a wide range of investigations of this disease ranging from large seroepidemiologic studies to novel treatment trials to collaborative studies on COVID immunology.  Studies that could potentially take a fellow include:

• Large seroepidemiologic, longitudinal studies of COVID in the counties throughout California both before and after the initiation of vaccines.   We have collected data sets that allow us to understand risk factors for breakthrough infections,  how vaccination and other interventions change behavior,  and the role of natural infection in building immunity.
• Studies on COVID infection, immunity and vaccination in patients receiving dialysis
• A clinical trial of camostat, a TMPPRS2 blocker, that prevents SARS-CoV2 from entering cells.
• Studies that define the normal human body temperature in children and adults
• Research on how skin care in babies varies across populations and how this influences skin integrity and development of allergic diseases later in life (with Kari Nadeau).
• Studies on the development of the pediatric virome, microbiome and immunome in the first three years of life.

The Idoyaga Lab is focused on the function and biology of very unique cells of the immune system, Dendritic cells (DCs). DCs are specialized antigen-presenting cells that initiate and modulate our body’s immune responses to invading microbes. DCs also play a crucial role in maintaining immune unresponsiveness to our own tissues and environmental and/or innocuous substances. Considering their importance in orchestrating the quality and quantity of immune responses, DCs are an indisputable target for vaccines and therapies.

Statistical algorithms for genomics, RNA biology, splicing, cancer genomics, spatial transcriptomics

As a physician scientist with a clinical focus on osteoporosis, my laboratory focuses on stem cell sources for bone-forming osteoblasts, and osteoblast support of hematopoiesis in the bone marrow. In particular we are interested in the pathways that promote osteoblast differentiation, using genetically modified mice and lineage tracing techniques in vivo. We are also studying the role of the osteoblast niche in normal hematopoiesis and bone metastases from breast cancer.

Department URL:
https://medicine.stanford.edu/

The overall theme of our research has been the genetic basis of cardiovascular disease across the continuum from Discovery to the development of Model Systems to the Translation of these findings to the clinic and most recently to the Public Health aspect of genetics. Currently our Discovery and basic translational efforts center on understanding the genetic basis of insulin resistance using genome wide association studies coupled advanced genetic analyses such as colocalization with exploration using in vitro and in vivo model systems including induced pluripotent stem cells and and gene editing screens. 

The overall theme of our research has been the genetic basis of cardiovascular disease across the continuum from Discovery to the development of Model Systems to the Translation of these findings to the clinic and most recently to the Public Health aspect of genetics. Currently our Discovery and basic translational efforts center on understanding the genetic basis of insulin resistance using genome wide association studies coupled advanced genetic analyses such as colocalization with exploration using in vitro and in vivo model systems including induced pluripotent stem cells and and gene editing screens. 

Our interdisciplinary lab pursues research centered around advanced polymer 3D fabrication methods and their applications in human health. Focus areas include (1) creating new digital polymer 3D printing capabilities, such as single-micron resolution printing and novel multi-materials printing methods; (2) synthesizing new polymers for 3D printing, with interests in composites, bioabsorbable materials, and recyclable materials; and (3) employing our 3D printing materials and process advances for clinical applications in areas including: new medical device opportunities; vaccine platform development via the advancement of novel microneedle designs; precision delivery of therapies (molecular and cellular) and vaccines; molecular monitoring; and device-assisted, targeted drug delivery, including for cancer treatment. We also pursue novel digital treatment planning approaches using 3D printed medical devices, with our current focus on pediatric therapeutic devices. In this area, we are working with partners at Stanford to design devices and treatment planning solutions for babies with conditions including cleft palate and Pierre Robin Sequence. Complementing these research areas, our lab also emphasizes entrepreneurship; diversity, equity, and inclusion; implications of the digital revolution in the manufacturing sector; and strategies toward achieving a circular economy.ch

Our lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients. Our lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes.